Particle-mediated DNA delivery was used to administer a DNA vaccine against Hepatitis B to minipigs. The study represented one arm of the safety evaluation program for this product and was designed to assess local tolerance, acute toxicity, and biodistribution of the DNA plasmid. The vaccine was given to 4 groups of minipigs that were sacri ced at 2, 28, 56, or 141 days after treatment. The procedure was well tolerated with mild local skin reactions at 2 days postdosing and no evidence of systemic toxicity. By 28 days the skin lesions had regressed apart from a low grade perivascular mononuclea r cell in ltrate in the upper dermis, together with a small number of phagocytose d gold particles. This in ltrate persisted up to 141 days. The expressed HBsAg was detected by immunohistochemistr y in keratinocytes (usually in association with an intranuclear gold particle) at 2 days but not at later time points. Polymerase chain reaction (PCR) was used to assay treatment sites and selected internal organs to evaluate biodistribution and persistence of the DNA plasmid. At 2 days the plasmid was detected in the treatment sites and also in the inguinal lymph nodes. At day 57 it was present in the treatment sites only and by day 141 appeared to have cleared. The results from this study demonstrate that particle-mediated gene delivery was well tolerated in the minipig. The biodistribution and persistence of the plasmid was within acceptabl e limits for this type of vaccine. As the minipig is regarded as a good model for humans these data support the concept that particle-mediated DNA delivery will be safe in human clinical applications.
INTRODUCTION
DNA vaccines offer a novel approach to immunization and are currently being evaluated for safety and ef cacy in human clinical trials (5) . Earlier studies have shown that these vaccines are superior to protein vaccines, in a variety of murine and primate disease models, as they generate both humoral and cellular immune responses (10, 26) . The endogenous production of antigen by the host cell transcriptional machinery mimics aspects of live attenuated vaccines without the associated risk of potential pathogenic replication. Also, they can be manufactured in a cost-effective manner and stored with relative ease at room temperature (5) . DNA vaccines are being developed primarily for the treatment of cancer and for prevention or therapy of infectious diseases (10) .
Previous clinical trials of DNA vaccines employed intramuscular inoculation of DNA in saline. These studies demonstrated that DNA vaccines were safe and well tolerated in humans, but there was substantially lower ef cacy than expected based on the results from animal studies (15, 28) . In addition, the doses of vaccine required to induce a detectable immune response were considerably higher in humans than in mice (16) . It is expected that cutaneous DNA vaccination can effectively transition from rodents to humans without a reduction in ef cacy or the requirement for a signi cant increase in vaccine dose (25) . The presence of a large population of antigen presenting cells (Langerhans cells) in the epidermis provides the basis for the immune response after DNA vaccination by the cutaneous route (22) .
Here we describe the results of a preclinical safety study with a DNA vaccine intended for Hepatitis B prophylaxis. The vaccine was administered to minipigs using the needlefree PowderJect system that propels gold particles coated with plasmid DNA directly into the skin (particle-mediated DNA delivery). Elsewhere this procedure has been variously described as Biolistic, Accell, or gene-gun delivery (2, 3, 7, 16) . Although histomorphologic aspects of this type of DNA delivery were described recently in guinea pigs and mice (27) , we believe this to be the rst report from studies utilizing a relevant animal model that allowed predictive assessment of local tolerance in humans.
An important safety concern with the use of DNA vaccines is the inappropriate distribution of the plasmid DNA outside the treatment site with the possibility of toxicity or 298 0192-6233/02$3.00 $0.00 integration into the host genome. Accordingly, we provide results from the biodistribution studies where selected tissues were analyzed for the presence of the plasmid DNA using the polymerase chain reaction (PCR).
METHODS

Animals
Twenty male and 20 female Gottingen minipigs (Ellegaard, Denmark) were used. The animals were 3 to 4 months old and weighed from 6 to 8 kg at study initiation. They were housed individually in oor pens with softwood sawdust bedding (Lignocell 3-4; Hahn and Co, Germany). The room was environmentally controlled with a 12-hour light cycle. Approximately 175 g of commercial minipig diet (C Peterson A/S, Denmark) was provided twice daily. Drinking water was available ad libitum.
Immunizations
Inoculations were carried out using a recombinant plasmid DNA construct (pWRG7128) encoding the entire sequence of Hepatitis B Virus surface antigen (HBsAg) ( Figure 1 ). The preparation of the plasmid DNA construct is given in detail elsewhere (25) . Puri ed DNA was precipitated onto the surface of 1 to 3 l m gold particles (DeGussa Metals Group, South Plain eld, NJ) in the presence of spermidine (Sigma Chemical Co, St. Louis, MO) and calcium chloride (Fujisawa Inc, Melrose Park, IL) as previously described (16, 25) . Each dose contained a theoretical maximum of 1.0 l g DNA precipitated onto 0.5 mg of gold. For each delivery, a nozzle-cassette containing DNA-gold was placed onto the PowderJect XR2 device (PowderJect Vaccines Inc, Madison, WI), which uses medical grade, lter-sterilized helium to administer the DNA-gold into the skin. DNA was delivered at a constant helium pressure of 500 pounds per square inch (psi). The vaccine was administered to the shaved ventral abdominal skin of anesthetized minipigs with the deliveries being equally spaced, as far apart as possible, in 2 rows on either side of the midline. 1  4  4  0  2  2  4  4  12  2  3  4  4  12  28  4  4  4  12  56  5  4  4 12 141
Study Design
This study represented one arm of the safety evaluation program for this product and was designed to assess local tolerance, acute toxicity, and biodistribution of the DNA plasmid. The aim was to evaluate these parameters following the administration of the proposed maximum cumulative clinical dose on a single occasion. The study comprised 5 groups of minipigs (Table 1) . Twelve separate vaccine deliveries were administered, at the same time point, to each minipig and the animals sacri ced after 2, 28, 56, or 141 days (Groups 2-5). One control group was left untreated (Group 1) and then sacri ced on day 2. The 2-day timing was scheduled primarily to assess local tolerance and acute toxicity whereas the later euthanasias were spaced to assess biodistribution and persistence of the DNA plasmid.
Clinical Observations
Treatment sites were examined at 4, 24, and 48 hrs after dosing. Any signs of ill health were recorded daily. Blood samples were taken from animals in Groups 1, 4, and 5, at 5 minutes and 24 hours after dosing, for examination by polymerase chain reaction (PCR) for the presence of plasmid DNA. These samples were taken in ethylene diamine tetra-acetic acid (EDTA) and stored at 4 C prior to DNA extraction.
Necropsy and Tissue Sampling
At necropsy a full macroscopic examination was performed on each animal. Samples from the following organs were collected and xed in 10% neutral-buffered formalin: skin (treated and untreated samples), lymph nodes (super cial cervical, axillary, super cial inguinal and subiliac), spleen, lungs, liver, kidney, heart, brain, testes, and ovaries. These tissues were embedded in paraf n wax, sectioned at 3 to 5 l m, and stained with hematoxylin and eosin (H&E) for histopathological evaluation. Histologic sections were produced from the greatest diameter of the treatment site.
Tissues were also harvested from these animals for plasmid biodistribution studies using PCR. For this assay, frozen samples were taken from the following organs and stored at 80 C prior to DNA extraction: skin (treated and untreated samples), lymph nodes (super cial cervical, axillary, supercial inguinal and subiliac), spleen, lung, liver, testes, and ovaries. The super cial cervical and axillary nodes were combined prior to DNA extraction, and the super cial inguinal and subiliac were maintained as separate samples. In addition, samples of blood and bone marrow were collected from all animals (in EDTA) and stored at 4 C prior to extraction. Special precautions, in accordance with that previously described, were taken at necropsy to ensure that cross-contamination between animals, and also between organs or treatment sites within the same animal, were avoided (11) .
Immunohistochemistry
Formalin-xed, paraf n-embedded sections of skin and lymph nodes were sectioned at 3-5 l m and stained immunohistochemically to demonstrate HBsAg. First, the sections were incubated with 0.5% hydrogen peroxide in methanol to inhibit endogenous peroxidases. Nonspeci c protein binding was then blocked using normal rabbit serum diluted 1:5 in tris buffered saline (TBS). A mouse monoclonal antibody raised against HBsAg. (1:10; DAKO A/S, Denmark) was applied overnight at 4 C in a humidity chamber. After washing in TBS, biotinylated rabbit anti-mouse immunoglobulins (1:100; DAKO A/S) were applied for 30 minutes. Finally the slides were incubated with StreptABComplex/HRP (DAKO A/S) for 30 minutes, developed in freshly prepared DAB solution, and counterstained with Mayers hematoxylin. Negative controls included: omitting the primary antibody from this procedure, the staining of untreated skin, and the replacement of the primary antibody with an isotype-matched control (Mouse IgG1, DAKO A/S). Liver sections taken from a human patient with chronic hepatitis (and known to be HBsAg seropositive) were used as positive controls.
DNA Extractions
Genomic DNA extractions were performed with Genomic Tips (100/G) (Qiagen, Crawley, UK) based on the supplier's Tissue Protocol for either blood (4 ml per sample) or tissues (80 mg per sample). DNA was resuspended in 10 mM Tris HCl (pH 8.5) and the concentration and purity determined by A 260 /A 280 spectroscopy. The extracted DNA samples were stored at 20 C prior to analysis.
PCR Methods and Gel Electrophoresis
Endpoint PCR was used to evaluate all samples to determine whether plasmid DNA was present at a speci c level of sensitivity. Both high and low sensitivity assays were developed for use in this study. The low sensitivity assay could detect 10 femtograms (fg) of plasmid DNA (approximately 1,700 copies) per l g of genomic DNA and was developed speci cally to analyse the treatment sites at 2 days after treatment when large quantities of plasmid DNA were expected to be present. The high sensitivity assay was able to detect 500 attagrams (ag) of plasmid DNA (approximately 85 copies) per l g of genomic DNA, and was developed for the analysis of treatment sites taken at later time points and all other samples in this study. Validation experiments for the high and low sensitivity assay consistently produced positive results at the required level of sensitivity in the presence of minipig DNA. Plasmid DNA was used as positive control material and diluted in nuclease-free water to a concentration of 1000 fg/l L, divided into 30-l l aliquots and stored at 20 C. These aliquots were freshly diluted to 500 ag/l L on the day of the PCR run and provided the positive control for spiking of test samples.
For each test sample, PCR ampli cation was performed in duplicate on approximately 1 l g minipig genomic DNA. One of the test duplicates was spiked with 500 ag of plasmid DNA to verify the absence of PCR inhibitors in the DNA extract. Two identical 'no DNA' negative control reactions were included to con rm the absence of reagent contamination. In addition, a positive control using plasmid DNA (500 ag) was included in each PCR experiment. Primer sequences (I primer set) were obtained from PowderJect Vaccines (Madison, WI): BF39 (5 CGAACATGGAGAACATCACATCAGG) and BB46 (5 TAAAACGCCGCAGACACATCCAGC). These primers were speci c for a plasmid sequence in the region encoding the HBsAg and yielded a 245 base pair (bp) product.
Two PCR cycle conditions were used as part of the high sensitivity assay during the course of this study. These cycle conditions were equivalent in terms of sensitivity in that they were able to detect 500 ag of plasmid DNA per l g of genomic DNA and both were validated independently. The conditions for the high sensitivity assay were as follows: cycle 1: 94 C for 10 minutes (1 cycle), 94 C for 45 seconds, 63 C for 1 minute (45 cycles), 72 C for 6 minutes; cycle 2: 95 C for 13 minutes (1 cycle), 95 C for 30 seconds, 63 C for 30 seconds, 72 C for 1 minute (10 cycles), 92 C for 30, 63 C for 30 s, 72 C for 1 minute (50 cycles), 72 C for 10 minutes. Ampli cation was performed with a PCR thermocycler (MJ Research, Waltham, USA) with the following reagents: 0.5 l M of each primer, 0.2 mM of each dNTP, 2.0 mM MgCl 2 , 1xPCR Amplitaq Gold buffer and 2.5 units of Amplitaq Gold DNA polymersase (PE Applied Biosystems, Warrington, UK). The cycle conditions for the low sensitivity assay were as follows: 95 C for 2 minutes (1 cycle), 95 C for 1 minute, 60 C for 1.25 minutes, 72 C for 1 minute (34 cycles) and 72 C for 10 minutes.
The possibility of a false negative result from any tissue examined, due to the presence of PCR inhibitors in the genomic DNA sample, was excluded by spiking a duplicate DNA sample with plasmid DNA (500 ag). For those DNA samples where PCR of the duplicate plasmid DNA spiked sample did not produce a band at 245 bp (indicating PCR inhibition), the results for that sample were interpreted as noninformative (NI). These samples were then re-examined in a subsequent run using a further aliquot of the sample. If these samples continued to demonstrate PCR inhibition, then a DNA cleanup procedure using phenol/ chloroform extraction was used prior to rerunning the PCR. In those runs where a positive signal was obtained in the negative control reactions, no results were interpreted and the run was repeated. PCR products were analyzed by electrophoresis on a 2% agarose gel, stained with ethidium bromide, and photographed under UV illumination.
Samples Analyzed by PCR
The number of samples examined was in compliance with the current FDA guidelines (1) . For each organ, 3 separate samples were analysed, with the exception of the following: testes (5 samples), ovary (2 samples), and lung (2 samples). In the case of blood and bone marrow, a single sample taken at each time point was analysed. Details of the total number of samples examined per group are listed in Table 2 . All samples taken for the PCR assay at 2 and 28 days were analyzed. Only those tissues that were found to be positive at 28 days (Group 3), were then examined at subsequent time points (Groups 4 and 5). 
RESULTS
Clinical and Macroscopic Findings
Within minutes of administration, a central zone of mild to moderate erythema appeared at the treatment site. This reached a maximum intensity at 24 hours, accompanied by very slight crusting ( Figure 2 ), and then subsided within a few days. In addition, a red-brown hue developed across the site that became mild to negative within 5 to 7 days. Mild swelling up to 10 to 12 mm in diameter was observed in a number of sites within 5 minutes of dosing but subsided within 24 to 48 hours. In none of the pigs was there any indication of discomfort or pruritis at the treatment sites. At the necropsies, with the exception of the treatment sites at 2 days postdosing, no macroscopic treatment related changes were observed.
Histopathology and Immunohistochemistry: 2 Days Posttreatment
Mild changes were present at the treatment sites at this time point. The epidermis was irregularly thickened and contained focal shallow erosions. Intact epidermis was overlain by a super cial band of crusting, of variable thickness, containing neutrophil leukocytes and necrotic keratinocytes (Figure 3) . Increased mitoses and light neutrophil in ltration were observed within the epidermal basal layers. Perivascular and scattered in ammatory cells were present in the upper dermis, comprising neutrophil leukocytes, lymphocytes, and macrophages.
The majority of gold particles were located in the stratum corneum and areas of crusting. Elsewhere, particles were scattered individually within keratinocytes throughout all layers of the viable epidermis. In the upper dermis, a small number of phagocytosed gold particles were present in macrophages ( Figure 4 ) and occasionally an extracellular particle was visible.
Small numbers of keratinocytes staining positively for HBsAg were observed at all treatment sites. These cells were individually scattered throughout all layers of the viable epidermis and exhibited a diffuse cytoplasmic signal. In the majority of positively stained cells a nuclear gold particle was present ( Figure 5 ). In the dermis a positive signal for HBsAg was observed at only 1 treatment site; the cell involved being a macrophage containing nuclear gold particle. A consistent feature was the presence of a thin band of positive staining at the base of the stratum corneum ( Figure 6 ). This was seen only in the skin of treated animals and not in untreated controls. The bands of staining in the stratum corneum were usually present in association with positively stained cells in the most super cial layer of the stratum granulosum. Similar bands of immunopositivity were not observed in treated skin following application of the isotype control antibody.
No signi cant staining was observed at the treatment sites with any of the negative controls. Membranous and cytoplasmic staining for HBsAg was noted in the human liver sections used as positive controls. These staining patterns are consistent with those previously reported in chronic HBV infection (4) .
A small number of phagocytosed gold particles were present within macrophages in the cortex and medulla of the super cial inguinal and subiliac lymph nodes. No other morphological changes nor positive signals for HBsAg were present in these drainage nodes.
Histopathology and Immunohistochemistry: 28 Days Posttreatment
By 28 days considerable regression of the skin changes had taken place. Epidermal morphology was normal, although a few gold particles were present, mostly in basal layers. A low grade in ltrate of perivascular macrophages and lymphocytes persisted in the upper dermis. Small numbers of macrophages containing phagocytosed gold particles were present within the in ltrate. No positive signals for HBsAg were observed at the treatment sites. Phagocytosed gold particles were observed in macrophages in the super cial inguinal and subiliac lymph nodes in a similar manner to those seen at 2 days posttreatment.
Histopathology and Immunohistochemistry: 56 and 141 Days Posttreatment
At both these time points, the treatment sites were of similar histologic appearance. A sparse number of isolated gold particles were noted in the epidermis, mostly in nuclei in the basal layer (Figure 7 ), but occasionally a particle was observed in the upper layers including the stratum corneum. The Phagocytosed gold particles were observed in macrophages in the super cial inguinal and subiliac lymph nodes in a similar manner to those seen at 2 and 28 days posttreatment. No treatment related histopathologic changes were observed in any of the tissues outside the treatment sites at all time points.
PCR Biodetection
Three treatment sites from each animal were examined by PCR and therefore a total of 24 sites were examined from each group. At 2 days after dosing, the DNA plasmid was present at levels equal to, or greater than, 10 fg per mg of genomic DNA in 23/24 (96%) treatment sites ( Table 2) . By 56 days, 13/24 (54%) sites were positive (Figure 8 ). However, at 141 days none of the sites proved positive.
A single blood sample taken at 24 hours, and 1 taken at 2 days (necropsy) were positive. By 28 days all blood samples were negative. Although all bone marrow samples collected at 2 days were negative, a single bone marrow sample was positive at 28 days. All bone marrow samples examined at 56 days were negative.
At 2 days after treatment, 2 of 8 inguinal lymph node samples were positive. Other tissues examined (ie, spleen, lung, liver, ovary, and testis) were negative at 2 and 28 days. All samples examined from control animals (group 1) proved negative.
In a small number of samples, representing most of the tissues examined, a noninformative result was obtained that represented a failure of the positive spiked sample in the assay (see previously).
DISCUSSION
Signi cant overlap between DNA vaccines and gene therapies exist in terms of safety issues (9) . In these therapeutic areas, regulatory agencies require that preclinical safety testing is performed in relevant animal models where the biological response to therapy is expected to mimic the human response (8) . Pig skin is well established as a relevant model for human skin with regards to morphology, physiology, and response to epicutaneously applied drugs (13, 14, 19, 29) . Gottingen minipigs were used in our preclinical safety program because they are biologically well characterized as a toxicologic species (17) .
Generally, at the treatment sites the device was well tolerated with the induction of pathologic changes consistent with mild impact trauma. These changes were evident macroscopically as reddening, crusting, and mild swelling. By 28 days posttreatment, all lesions had completely regressed apart from the low grade perivascular mononuclear cell inltrates that persisted in the dermis up to day 141. Dermal perivascular in ammatory cell in ltration would appear to be a nonspeci c response of the porcine skin to various injurious stimuli (29, 30) . In this study the persistence of the in ammation was presumably due to the continued presence of phagocytosed gold particles within a small number of the constituent macrophages.
At 2 days, the gold particles were distributed primarily within the epidermis but also focally in the upper dermis mostly phagocytosed within macrophages. In addition, at this stage a small number were present in the drainage lymph nodes. The majority of the epidermal gold had sloughed by 28 days as would be expected given the 30 day epidermal turnover time of the porcine epidermis (20) . The red-brown hue, visible macroscopically at the delivery site, was considered to be due to the presence of super cial gold particles. This discoloration disappeared over 5 to 7 days probably with the sloughing of the majority of the gold. At days 28, 56, and 141 a very small number of epidermal gold particles remained; most of these were in basal cells but an occasional particle was noted within a keratinocyte at a higher level, for example, stratum spinosum. Presumably these particles were initially delivered into basal stem cells where they remained until released into a differentiating daughter cell. In this way a gold particle could remain within a stem cell for a long period before ascending the epidermis within a differentiating keratinocyte.
The persistence of very small numbers of gold particles in the dermis and lymph nodes was not unexpected and is not considered to constitute a safety hazard with this procedure. The gold particles were composed of metallic (elemental) gold, which is arguably the most biologically inert of all metals and-despite its widespread use as a prosthesis-rarely triggers immune responses (18) .
DNA immunization via particle-mediated delivery depends on the transfection of viable cells to synthesize the immunogenic protein. In this study epidermal keratinocytes containing HBsAg were present at all treatment sites at 2 days. Other workers have also reported that epidermal keratinocytes were the primary cell type expressing immunogenic protein following gene-gun delivery (22, 24, 27) . The sparse and scattered distribution of these immunopositive cells was consistent with the distribution of gold particles within the epidermis. The presence of thin bands of immunopositivity at the base of the stratum corneum was an unexpected nding. Careful examination of control sections determined that this was valid corneal staining for HBsAg.
These bands were considered to be epidermal cells that had undergone keratinization after transfection, yet the antigenic integrity of the expressed HBsAg had been maintained. We were unable to demonstrate HBsAg in drainage lymph nodes; however, this was not unexpected as it has been shown elsewhere that lymph node cells expressing DNA encoded antigen following this mode of administration are rare (22) .
A gold particle was usually present within the nucleus of a cell that exhibited a cytoplasmic signal for HBsAg. This is consistent with the observations of others where penetration of the nucleus by the DNA-coated gold particle was essential for protein expression to occur [Joel Haynes, Powder-Ject Vaccines Inc; personal communication, May 2001]. The absence of a gold particle from the nucleus of HBsAg positive cell could be attributed to a plane of section effect. No immunopositivity was observed in numerous epidermal cells where a gold particle was visible clearly within the cytoplasm.
All positive staining for HBsAg was present at the treatment sites at 2 days with no signals being observed at later time points. This is to be expected as the rate of epidermal turnover would lead to the loss of the majority of gold particles (and presumably plasmid DNA) by 28 days (23) . It has been shown in vitro that cytokines such as interferon c (IFN-c ) and tumor necrosis factor-a (TNF-a) can inhibit transgene expression from the human cytomegalovirus promoter (23) . Such promoter attenuation could account for the lack of immunopositivity associated with the very small numbers of gold particles present in the epidermis at 28 days. Other reasons that could account for this include degradation of the plasmid DNA and secretion of the expressed HBsAg from the keratinocytes.
There is a concern that DNA vaccines may induce responses against self-antigens, thereby triggering the development of autoimmune disease (12) . No evidence of systemic toxicity was observed in this study following the administration of a single dose of DNA vaccine although this did result in seroconversion (data not shown). A signi cant advantage of using skin as the delivery site for this type of product (rather than muscle) is that the majority of gold particles, exogenous DNA, and transfected protein should be shed relatively quickly from the surface as part of the normal epidermal turnover. This will help reduce potential adverse effects such as the induction of tumors and autoimmunity (27) .
In safety studies with DNA vaccines, it is customary to assess the biodistribution of the DNA plasmid in order to provide information on potential toxicities (11) . Selective use of a low and high sensitivity PCR assay in this study provided additional information about relative levels of plasmid within tissues. The high sensitivity assay detected as few as 85 copies of plasmid per ug of genomic DNA and this level of sensitivity satis es current recommendations for biodistribution studies (9) . In most tissues, a sample of 1 l g of genomic DNA corresponds to approximately 150,000 genomes (21) and this is considered to be a suitable number of cells to survey for the presence of the plasmid.
Plasmid DNA that is carried into the dermis on gold particles could possibly undergo two fates. First, the DNA may be degraded at the site either intra-or extracellularly. Alternatively, the DNA could be transported either within cells or within blood or lymph to remote sites. The absence of plasmid in the blood at 5 minutes postdosing indicates that it is not gaining direct entry to the vascular system. However, the plasmid appeared to be entering the vascular system at 24 and 48 hours postdosing with an incidence of 1/16 and 1/8 positive blood samples, respectively. This may be related to cellular transport of the plasmid. Evidence of such transport was provided by the discovery of plasmid in the draining inguinal lymph nodes in a minority of animals at 2 days. The presence of DNA plasmid in the blood stream and lymph nodes was not considered to have safety implications as complete clearance from these sites was demonstrated at 28 days after treatment. A positive PCR signal was obtained from a single bone marrow sample at 28 days. However, considering there were no positive results from this tissue at 2 days following dosing, it seems likely that this positive nding may have resulted from contamination of the sample with plasmid DNA either at necropsy or during sample analysis.
At 2 days postdosing, plasmid was detected at signi cant levels (greater than 10 fg plasmid/l g genomic DNA) in 96% (23/24) of the treatment sites examined, thus demonstrating the ef ciency of the dosing procedure. The reason for the negative result in 1 treatment site is unclear but it may have resulted from a sampling error either at tissue collection or the DNA extraction stage. By 28 days, 74% (14/19) of the treatment sites were positive using the high sensitivity assay (greater than 500 ag plasmid/l g genomic DNA). By 56 days 54% (13/24) of the treatment sites were positive again using the high sensitivity assay with all the sites from 25% (2/8) of animals being negative. No plasmid was detected in any of the treatment sites at 141 days postdosing. These results demonstrate a gradual progressive loss of DNA plasmid from the skin, with the levels of plasmid falling to undetectable levels at a point somewhere between 56 and 141 days after dosing.
After treatment, the majority of gold particles, presumably with associated plasmid DNA, are located within the epidermis. As mentioned before, the normal turnover of epidermis would lead to the loss of the majority of gold and plasmid by 28 days. The inability to detect DNA plasmid in the treatment sites, or in any of the other tissues examined at 141 days after dosing, eliminates any safety concerns over plasmid persistence. Regulatory guidelines suggest that a persistent PCR signal for a vector will require investigation to exclude integration into the host genome of germ cells (6) . In this study, there was no persistence of the plasmid and therefore no assessment of genomic integration was required. In addition, it is worth emphasizing that no plasmid was detected in the ovaries or testes at any time point in this study.
In summary, the results from this study demonstrate that particle-mediated gene delivery was well tolerated in the minipig with mild local skin reactions and no evidence of systemic toxicity. The biodistribution and persistence of the plasmid was within acceptable limits for this type of vaccine. As the minipig is regarded as a good human model, these data support the concept that particle-mediated DNA delivery will be safe in human clinical applications.
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